By Karen Roman Agendia, Inc. said its gene expression profiling test MammaPrint can predict extended endocrine therapy benefit for patients with early-stage breast cancer. The test helps optimizing additional therapy and can potentially improve survival, the company said. “These...

By Daniella Parra ReAlta Life Sciences said it appointment Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of its Board of Directors, as it continues to rebalance the inflammatory response to address rare and acute inflammatory diseases across a wide spectrum...

By Daniella Parra MOBILion Systems, Inc. said it formed a Proteomics Advisory Board of seven prominent experts to guide its efforts in proteomics, focusing on advancing complex sample analysis technology. The approach aims to revolutionize mass spectrometry by enabling precise...

By Daniella Parra Medera Inc. and CADENCE have launched Asia’s first cardiac gene therapy trial for heart failure in Singapore, they said. The trial uses SRD-001, an adeno-associated virus-based therapy targeting heart failure with reduced ejection fraction, they said. “The...

By Karen Roman Healthcare apparel brand FIGS, Inc. (NYSE: FIGS) said it expects flat net revenue growth and an adjusted EBITDA margin around 8% for fiscal year 2024. Net revenue was $140.2 million in the third quarter, down 1.5%, while...

By Karen Roman Radella Pharmaceuticals, LLC. announced the successful trial results of MD-18, its leading program to treat obesity and diabetes. The company will start the next phase applying multiple doses of MD-18 before the end of the year, it...

By Karen Roman DecisionRx said it appointed Michael Tilton as Chief Growth Officer to lead the expansion of the company’s Medication Therapy Optimization platform. Tilton’s previous roles include senior vice president at Humana, as well as other senior leadership positions...

By Daniella Parra Aktis Oncology said AKY-1189 is showing promise to treat cancers such as metastatic urothelial carcinoma, breast, lung, colorectal and cervical cancers. The company said data from an oral plenary and two posters highlighted significant tumor uptake and...

By Karen Roman Biotechnology company Medera Inc. said it will start the Cohort B (high-dose) trial of SRD-002, the first-in-human cardiac gene therapy for Heart Failure with Preserved Ejection Fraction. The company finished Cohort A (low-dose) with favorable efficacy results after...

By Daniella Parra March Biosciences has closed an oversubscribed $28.4 million Series A financing, led by Mission BioCapital and 4BIO Capital to advance its innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy and more, it said. The therapy is aimed...